Literature DB >> 24684608

Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice.

M S Sidorov1, D D Krueger1,2, M Taylor1, E Gisin1, E K Osterweil1,3, M F Bear1.   

Abstract

Fragile X (FX) is the most common genetic cause of intellectual disability and autism. Previous studies have shown that partial inhibition of metabotropic glutamate receptor signaling is sufficient to correct behavioral phenotypes in a mouse model of FX, including audiogenic seizures, open-field hyperactivity and social behavior. These phenotypes model well the epilepsy (15%), hyperactivity (20%) and autism (30%) that are comorbid with FX in human patients. Identifying reliable and robust mouse phenotypes to model cognitive impairments is critical considering the 90% comorbidity of FX and intellectual disability. Recent work characterized a five-choice visuospatial discrimination assay testing cognitive flexibility, in which FX model mice show impairments associated with decreases in synaptic proteins in prefrontal cortex (PFC). In this study, we sought to determine whether instrumental extinction, another process requiring PFC, is altered in FX model mice, and whether downregulation of metabotropic glutamate receptor signaling pathways is sufficient to correct both visuospatial discrimination and extinction phenotypes. We report that instrumental extinction is consistently exaggerated in FX model mice. However, neither the extinction phenotype nor the visuospatial discrimination phenotype is corrected by approaches targeting metabotropic glutamate receptor signaling. This work describes a novel behavioral extinction assay to model impaired cognition in mouse models of neurodevelopmental disorders, provides evidence that extinction is exaggerated in the FX mouse model and suggests possible limitations of metabotropic glutamate receptor-based pharmacotherapy.
© 2014 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Keywords:  Fragile X; instrumental extinction; intellectual disability; lovastatin; metabotropic glutamate receptor 5

Mesh:

Substances:

Year:  2014        PMID: 24684608      PMCID: PMC4182346          DOI: 10.1111/gbb.12137

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  37 in total

1.  Mildly impaired water maze performance in male Fmr1 knockout mice.

Authors:  R D'Hooge; G Nagels; F Franck; C E Bakker; E Reyniers; K Storm; R F Kooy; B A Oostra; P J Willems; P P De Deyn
Journal:  Neuroscience       Date:  1997-01       Impact factor: 3.590

2.  Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP.

Authors:  Y M Lu; Z Jia; C Janus; J T Henderson; R Gerlai; J M Wojtowicz; J C Roder
Journal:  J Neurosci       Date:  1997-07-01       Impact factor: 6.167

3.  Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse.

Authors:  Yann S Mineur; Frans Sluyter; Sanne de Wit; Ben A Oostra; Wim E Crusio
Journal:  Hippocampus       Date:  2002       Impact factor: 3.899

4.  Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.

Authors:  Emily K Osterweil; Dilja D Krueger; Kimberly Reinhold; Mark F Bear
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

5.  Lovastatin does not correct the accumulation of very long-chain fatty acids in tissues of adrenoleukodystrophy protein-deficient mice.

Authors:  T Yamada; N Shinnoh; T Taniwaki; Y Ohyagi; H Asahara; J Kira
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

6.  Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.

Authors:  Aubin Michalon; Andreas Bruns; Céline Risterucci; Michael Honer; Theresa M Ballard; Laurence Ozmen; Georg Jaeschke; Joseph G Wettstein; Markus von Kienlin; Basil Künnecke; Lothar Lindemann
Journal:  Biol Psychiatry       Date:  2013-07-30       Impact factor: 13.382

7.  Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Authors:  Aubin Michalon; Michael Sidorov; Theresa M Ballard; Laurence Ozmen; Will Spooren; Joseph G Wettstein; Georg Jaeschke; Mark F Bear; Lothar Lindemann
Journal:  Neuron       Date:  2012-04-12       Impact factor: 17.173

8.  The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice.

Authors:  M F Vinueza Veloz; R A M Buijsen; R Willemsen; A Cupido; L W J Bosman; S K E Koekkoek; J W Potters; B A Oostra; C I De Zeeuw
Journal:  Genes Brain Behav       Date:  2012-01-19       Impact factor: 3.449

9.  Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model.

Authors:  Ioannis Kramvis; Huibert D Mansvelder; Maarten Loos; Rhiannon Meredith
Journal:  Front Behav Neurosci       Date:  2013-11-21       Impact factor: 3.558

Review 10.  Dopaminergic control of cognitive flexibility in humans and animals.

Authors:  Marianne Klanker; Matthijs Feenstra; Damiaan Denys
Journal:  Front Neurosci       Date:  2013-11-05       Impact factor: 4.677

View more
  10 in total

1.  Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome.

Authors:  Michael S Sidorov; Matthew C Judson; Hyojin Kim; Marie Rougie; Alejandra I Ferrer; Viktoriya D Nikolova; Natallia V Riddick; Sheryl S Moy; Benjamin D Philpot
Journal:  J Neurosci       Date:  2018-02-05       Impact factor: 6.167

Review 2.  Modeling fragile X syndrome in the Fmr1 knockout mouse.

Authors:  Tatiana M Kazdoba; Prescott T Leach; Jill L Silverman; Jacqueline N Crawley
Journal:  Intractable Rare Dis Res       Date:  2014-11

3.  Impaired cognitive discrimination and discoordination of coupled theta-gamma oscillations in Fmr1 knockout mice.

Authors:  Basma Radwan; Dino Dvorak; André A Fenton
Journal:  Neurobiol Dis       Date:  2016-01-12       Impact factor: 5.996

Review 4.  Striatal Circuits as a Common Node for Autism Pathophysiology.

Authors:  Marc V Fuccillo
Journal:  Front Neurosci       Date:  2016-02-09       Impact factor: 4.677

5.  Deletion of the KH1 Domain of Fmr1 Leads to Transcriptional Alterations and Attentional Deficits in Rats.

Authors:  Carla E M Golden; Michael S Breen; Lacin Koro; Sankalp Sonar; Kristi Niblo; Andrew Browne; Natalie Burlant; Daniele Di Marino; Silvia De Rubeis; Mark G Baxter; Joseph D Buxbaum; Hala Harony-Nicolas
Journal:  Cereb Cortex       Date:  2019-05-01       Impact factor: 5.357

6.  Role of the TRPC1 Channel in Hippocampal Long-Term Depression and in Spatial Memory Extinction.

Authors:  Xavier Yerna; Olivier Schakman; Ikram Ratbi; Anna Kreis; Sophie Lepannetier; Marie de Clippele; Younès Achouri; Nicolas Tajeddine; Fadel Tissir; Roberta Gualdani; Philippe Gailly
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

7.  Restoration of FMRP expression in adult V1 neurons rescues visual deficits in a mouse model of fragile X syndrome.

Authors:  Chaojuan Yang; Yonglu Tian; Feng Su; Yangzhen Wang; Mengna Liu; Hongyi Wang; Yaxuan Cui; Peijiang Yuan; Xiangning Li; Anan Li; Hui Gong; Qingming Luo; Desheng Zhu; Peng Cao; Yunbo Liu; Xunli Wang; Min-Hua Luo; Fuqiang Xu; Wei Xiong; Liecheng Wang; Xiang-Yao Li; Chen Zhang
Journal:  Protein Cell       Date:  2021-10-29       Impact factor: 14.870

8.  Normal Performance of Fmr1 Mice on a Touchscreen Delayed Nonmatching to Position Working Memory Task.

Authors:  Prescott T Leach; Jane Hayes; Michael Pride; Jill L Silverman; Jacqueline N Crawley
Journal:  eNeuro       Date:  2016-03-15

Review 9.  Translational tests involving non-reward: methodological considerations.

Authors:  Benjamin U Phillips; Laura Lopez-Cruz; Lisa M Saksida; Timothy J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2018-10-10       Impact factor: 4.530

10.  A Differential Effect of Lovastatin versus Simvastatin in Neurodevelopmental Disorders.

Authors:  Melania Muscas; Sang S Seo; Susana R Louros; Emily K Osterweil
Journal:  eNeuro       Date:  2020-08-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.